SIGA TECHNOLOGIES INC (SIGA) Form 10-Q — Aug 6, 2026
SIGA Technologies reported Q2 2026 revenue of $41.0 million, down roughly 49% from $81.1 million a year earlier, with net income of $12.5 million ($0.17 diluted EPS) versus $35.5 million ($0.49) in Q2 2025. Six-month revenue fell to $47.2 million from $88.2 million, and six-month net income dropped to $9.0 million from $35.1 million. The decline reflects the wind-down of the 19C BARDA contract: cumulative deliveries of $450.2 million of oral TPOXX and $76.8 million of IV final drug product to the Strategic Stockpile are complete, leaving only about $5.6 million of unexercised options. Q2 included $24.4 million of IV TPOXX sales to the U.S.
Key figures
- Eps
- 0.17
- Revenue
- 41002253
- Guidance
- Company forecasts full-year 2026 losses based on orders received to date; targeting Supplemental NDA submission to FDA for a smallpox post-exposure prophylaxis (PEP) indication in H1 2027
- Net Income
- 12463434
- Revenue Yoy
- -49.5%
- Total Assets
- 175736786
- Cash Position
- 117584444
- Shares Outstanding
- 71849716
- Q2 2025 revenue
- 81120004
- Cash dec 31 2025
- 154966414
- Total liabilities
- 10446151
- Q2 2025 net income
- 35483103
- Q2 2025 diluted eps
- 0.49
- Special dividend paid
- 43306649
- Six month revenue 2025
- 88160818
- Six month revenue 2026
- 47244834
- Barda exercised options
- ~$545.2 million
- Barda contract max value
- ~$630 million
- Barda unexercised options
- ~$5.6 million
- Six month net income 2026
- 9009184
- Effective tax rate q2 2026
- 16.1%
- Q2 2026 iv tpoxx sales usg
- $24.4 million
- Six month diluted eps 2026
- 0.13
- Special dividend per share
- 0.6
- Q2 2026 international sales
- $13.0 million
- Remaining performance obligations
- $24.9 million
- Operating cash flow six months 2026
- 6509840
Price after filing
Close on the filing date to close N calendar days later (from $3.24). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.